This page contains guidance issued by the GMMMG High Cost Drugs Subgroup. If you are an NHS healthcare professional working within the GM region and wish to submit information for consideration by the group please contact the professional secretary of the group via email

Document Title Issue Date Review Date Status
GMMMG PBR Ex Devices 2020-21 20200601 Jun 2020 20210401 Apr 2021 Under review
GMMMG PBR Ex Drugs 2020-21 20200601 Jun 2020 20210401 Apr 2021 Under review
GMMMG PBR Exclusions supporting information 20-21 20201001 Oct 2020 20211001 Oct 2021 Under review
Enabled Blueteq List 20210901 Sep 2021 updated monthly
Free of charge (FOC) medicines schemes 20200101 Jan 2020 20220101 Jan 2022
Position statement: Funding of high cost drugs when patients transition from children or adolescent services to adult services 20171001 Oct 2017 To be reviewed if national or GMMMG guidance changes
Sequential use of high cost drugs statement 20220601 Jun 2022
Commissioning framework for biologic medicines: defining best value 20180601 Jun 2018 To be reviewed if national or GMMMG guidance changes
Implementation and principles of a Greater Manchester biosimilar gainshare agreement 20170701 Jul 2017 To be reviewed if national or GMMMG guidance changes
Position statement for using biologic therapies to treat adult patients with Juvenile Idiopathic Arthritis (JIA) 20171001 Oct 2017 To be reviewed if national or GMMMG guidance changes
Botulinum toxin guidance 20200101 Jan 2020 20220101 Jan 2022
Teriparatide biosimilar uptake recommendation 20191101 Nov 2019 To be reviewed if national or GMMMG guidance changes